Chelsea Therapeutics is a biopharmaceutical development company
that acquires and develops innovative products for the treatment
of a variety of human diseases.
The Company is currently developing a library of metabolically
inert antifolate compounds engineered to have potent
anti-inflammatory and anti-tumor activity to treat a range of
immunological disorders. Early clinical data suggests that Chelsea's
lead antifolate compound, CH-1504, is a safe and effective treatment
alternative to methotrexate for RA and may have further
applications for psoriasis,IBDand certain cancers.
Chelsea's antifolate program is complemented by a strategic partnership
with Active Biotech ABfor
the joint development of the I-3D
portfolio of therapeutics targeting immune-mediated inflammatory
disorders and transplantation.
In addition to its autoimmune pipeline, Chelsea is pursing an orphan
drug strategy for the development
of Droxidopa,
an orally active synthetic precursor of norepinephrine, for the
treatment of neurogenic orthostatic hypotension. Currently approved
and marketed in Japan by Dainippon
Sumitomo Pharma Co., Ltd., Droxidopa has accumulated over
15 years of proven safety and efficacy, generating annual revenue
of approximately $50 million in Japan.
Founded in 2004 around its library of unique antifolate technology,
Chelsea has since raised over $35 million in additional capital,
transitioned into a public company and further expanded its product
development portfolio with early and late stage products candidates
that leverage the company’s development expertise and accelerate
the company’s drug commercialization efforts.
